Delving into the Latest Updates on Hydroxyzine Hydrochloride with Synapse

Overview

Basic Info

SummaryHydroxyzine is a first-generation antihistamine that is commonly used for the treatment of various allergic conditions such as hives and itching. It works by blocking the action of histamine, a chemical released in response to an allergic reaction. Histamine causes symptoms such as itching, swelling, and rash. Hydroxyzine is available in oral and injectable formulations. It is generally well tolerated by patients. However, side effects can include drowsiness, dizziness and dry mouth. It is important to note that there is ongoing research regarding the potential use of hydroxyzine to treat anxiety disorders, as it has shown some anxiolytic activity in preclinical studies.

Drug Type

Small molecule drug

Synonyms

Hychotine, Hydroxine, Hydroxizine

+ [13]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

UrticariaAnxiety DisordersDepressive Disorder+ [2]

Inactive Indication

Pruritus

Originator Organization

Pfizer Inc.

Active Organization

Shanghai Sine Pharmaceutical Co. Ltd.

Pfizer Inc.

Inactive Organization

Roerig SA

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (12 Apr 1956),

Anxiety DisordersPruritusUrticaria

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H29Cl3N2O2

InChIKeyANOMHKZSQFYSBR-UHFFFAOYSA-N

CAS Registry2192-20-3

The aim of this study is to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. By conducting a pilot study, we hope to provide initial data on the feasibility and potential impact of hydroxyzine for this population. This will inform the design and power calculations of a larger, more comprehensive study in the future.
Objectives:
To assess the feasibility of conducting a randomized controlled trial (RCT) of hydroxyzine for panic disorder.
To evaluate the effectiveness of hydroxyzine compared to TAU in reducing panic symptoms in patients with panic disorder.
To explore the potential side effects and tolerability of hydroxyzine in this population.
Methods:
This will be a single-center, open-label, randomized pilot study. A total of 30 patients with a primary diagnosis of panic disorder will be recruited from a psychiatric outpatient clinic. Participants will be randomly assigned to receive either hydroxyzine or TAU for 8 weeks. The primary outcome measure will be the change in panic symptoms as assessed by the Panic Disorder Severity Scale (PDSS). Secondary outcome measures will include the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression-Severity (CGI-S) scale. Participants will be assessed at baseline, 4 weeks, and 8 weeks. Adverse events will be monitored throughout the study.
Expected Results:
This pilot study is expected to provide preliminary data on the feasibility and potential efficacy of hydroxyzine for panic disorder. The results will inform the design of a larger RCT to further evaluate the efficacy of hydroxyzine for this population.
Significance:
There is a need for effective and well-tolerated treatments for panic disorder. If found to be effective, hydroxyzine could provide a new option for patients with this condition, potentially improving their quality of life and functioning. The results of this pilot study will inform the design of future studies and contribute to the development of evidence-based treatments for panic disorder.

Start Date30 Dec 2023

Sponsor / Collaborator

University of Sultan Qaboos

NCT05680584

/ RecruitingPhase 1IIT

Comparison Between the Effect of Oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in Pediatric Patients Undergoing Adenotonsillectomy

Comparison between the effect of oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in pediatric Patients Undergoing Adenotonsillectomy

Start Date01 Feb 2023

Sponsor / Collaborator-

100 Clinical Results associated with Hydroxyzine Hydrochloride

Login to view more data

100 Translational Medicine associated with Hydroxyzine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Hydroxyzine Hydrochloride

Login to view more data

1,583

Literatures (Medical) associated with Hydroxyzine Hydrochloride

01 May 2025·The Journal of Pediatrics

Prescription Trends of Medications Used to Treat Sleep Disturbances in School-Aged Children: An Interrupted Time-Series Analysis in France, 2016-2023

Article

Author: Kaguelidou, Florentia ; Acquaviva, Eric ; Trebossen, Vincent ; Gomez, Alexandre ; Valtuille, Zaba ; Peyre, Hugo ; Ouldali, Naim ; Bourmaud, Aurelie ; Sclison, Stéphane ; Revet, Alexis ; Delorme, Richard

OBJECTIVETo assess rates and trends of hypnotic medication prescriptions for children and adolescents.STUDY DESIGNCross-sectional study of national dispensing data between January 1, 2016, and December 31, 2023, in France. Prescriptions of hypnotic medications (hydroxyzine, alimemazine, melatonin, and Z-drugs) dispensed to children aged 6-17 years were analyzed. Monthly rates of hypnotic prescriptions per 1000 children were modeled before and after the pandemic onset (March 2020) to assess rate and trend changes. Rate ratios (RRs) were calculated between estimated and expected prescription rates.RESULTSOverall, 2 675 142 prescriptions were dispensed to an average yearly population of 9 963 497 children. In January 2016, prescription rate of hypnotic medications was estimated at 1.9 per 1000 and at 6.8 per 1000 in December 2023, with postpandemic onset rates exceeding the expected by 131% (RR: 2.31, 95% CI: 2.08; 2.54). Prescription trends increased for all medications from -0.1% (95% CI: -0.2; 0.1%) per month prepandemic to +1.4% (95% CI: 1.2; 1.6%) after the pandemic onset for hydroxyzine; +0.1% (95% CI: 0.0; 0.2%) to +0.9% (95% CI: 0.7; 1.0%) for alimemazine; +2.2% (95% CI: 2.0; 2.3%) to +4.4% (95% CI: 3.9; 4.9%) for melatonin; and -3.2% (95% CI: -3.6;-2.8%) to +1.8% (95% CI: 1.4; 2.2%) for Z-drugs. Monthly prescription rates exceeded the expected by 38% (RR: 1.38, 95% CI: 1.31; 1.46) for hydroxyzine; 19% (RR: 1.19, 95% CI: 1.15; 1.22) for alimemazine; 344% (RR: 4.44, 95% CI: 4.07; 4.80) for melatonin; and 419% (RR: 5.19, 95% CI: 4.24; 6.14) for Z-drugs.CONCLUSIONSRecent substantial increases in hypnotic medication prescribing for children are possibly related to their persistently deteriorating mental health, changes in prescribing strategies, and/or unmet pre-existing needs.

01 May 2025·Journal of Geriatric Psychiatry and Neurology

A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient

Review

Author: Chen, Anderson ; Metzger, Eran ; Osser, David ; Lee, Soyoung

BackgroundThis is a new algorithm from the Psychopharmacology Algorithm Project at the Harvard South Shore Program, focused on generalized anxiety disorder (GAD) in older adults. Pertinent articles were identified and reviewed.ResultsSelective serotonin reuptake inhibitors (SSRIs) are considered to be first-line medications, with a preference for sertraline or escitalopram. If avoiding sexual side effects is a priority, buspirone is an option for the relatively healthy older adult. If response is inadequate, the second recommended trial is with a different SSRI or one of the serotonin-norepinephrine update inhibitors (SNRIs), venlafaxine or duloxetine. For a third medication trial, additional alternatives added to the previous options now include pregabalin/gabapentin, lavender oil, and agomelatine. If there is an unsatisfactory response to the third option chosen, quetiapine may be considered. We recommend caution with the following for acute treatment in this population: benzodiazepines and hydroxyzine. Other agents given low priority but having some supportive evidence were vilazodone, vortioxetine, mirtazapine, and cannabidiol. Acknowledging that the median age of onset of GAD is in early adulthood, many patients with GAD will have been started on benzodiazepines (or other medications that require caution in the elderly) for GAD at a younger age. These medications may be continued with regular observation to see if the potential harms are starting to exceed the benefits and a switch to other recommended agents may be justified.

01 Apr 2025·Letters in Applied Microbiology

Screening of drugs with potential antifungal activity for repurposing in the treatment of cryptococcosis

Article

Author: Ferreira, Gabriella Freitas ; de Oliveira, Emanuel Almeida Moreira ; Lang, Karen Luise

AbstractCurrent therapeutic alternatives for the treatment of cryptococcosis are scarce, highly toxic, expensive, and difficult to access. Therefore, the aim of this study was to evaluate the anticryptococcal potential of a collection of 27 drugs in vitro against several strains of Cryptococcus neoformans and Cryptococcus gattii. We investigated several parameters to evaluate the antifungal activity of the drugs: determination of minimum inhibitory concentration (MIC), combinatorial effects with fluconazole, kinetics of growth inhibition, post-antifungal effect (PAFE), and morphometric analyses at subinhibitory concentrations. Antiparasitics albendazole, fenbendazole, flubendazole, mebendazole, and antidepressants duloxetine and paroxetine showed antifungal activity with an MIC of 100 µmol l−1 or less for most strains tested. The results of the zero-interaction power model indicated additive effects for combination of fluconazole with drugs finasteride, hydroxyzine, and paroxetine. The combined treatments significantly improved the ability of fluconazole to kill C. neoformans ATCC H99. Same phenomenon occurred in the in vitro PAFE, as the combinations suppressed fungal growth more effectively than fluconazole alone. A significant reduction in capsule size was observed. Screening of the drug collection showed interesting results, with benzimidazoles antiparasitics and serotonin and norepinephrine reuptake inhibitors in foreground. Finasteride, hydroxyzine, and paroxetine significantly improved activity of fluconazole in vitro.

100 Deals associated with Hydroxyzine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00672	Hydroxyzine Hydrochloride	N05BB01	DB00557

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Urticaria	Japan	Pfizer Inc.	28 Mar 1979
Depressive Disorder	Japan	Pfizer Inc.	30 Sep 1965
Eczema	Japan	Pfizer Inc.	30 Sep 1965
Nausea and vomiting	Japan	Pfizer Inc.	30 Sep 1965
Anxiety Disorders	China	Shanghai Sine Pharmaceutical Co. Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05126459 (CTgov)	Phase 3	Dental Caries	60	Meperidine+Hydroxyzine +Midazolam (Regimen 1)	hnmyaetyyt(cvtmbydqqi) = okekijalvx smbklauhsl (elkqdkulwp, vbayrpldhm - fdgikfnotz) View more	-	02 Oct 2024
				Meperidine+Hydroxyzine (Regimen 2)	hnmyaetyyt(cvtmbydqqi) = kszdouyshp smbklauhsl (elkqdkulwp, ssctlcxbqr - ftqamjcofu) View more
NCT04068948 (CTgov)	Phase 4	Sedation \| Dental Caries	37	Meperidine+Midazolam+Hydroxyzine (Midazolam, Hydroxyzine, Meperidine)	gymjbfykmf(iilgpwblbv) = msfqyonbke pxooclxngh (fkaoovnizg, ppihsavfrx - wsrnotrewd) View more	-	05 Dec 2023
				Midazolam+Hydroxyzine (Midazolam, Hydroxyzine)	gymjbfykmf(iilgpwblbv) = ultlrfychh pxooclxngh (fkaoovnizg, biymkocrbz - ohtinryhgr) View more
NCT04188106 (HAVE, CTgov)	Phase 4	Nausea \| Dyssomnias \| Smoking Cessation	26	Varenicline Pill+Hydroxyzine Pill	tsbsgvpcrt(nirnmblckb) = mtsbfyrkrz kqztmwahfo (fqrvtsgueq, nudzcysrrv - cxydukdesk) View more	-	03 Mar 2023